431 results about "Gemcitabine" patented technology

The present invention is for novel compositions and methods for treating cancer, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include liposome entrapped gemcitabine in which the liposome can contain any of a variety of neutral or charged liposome-forming compounds including cardiolipin.

The present invention concerns methods for treating cancer, such as pancreatic cancer, using combination therapies, including the combination of a synthetic triterpenoid, e.g., CDDO-Me, and gemcitabine.

The application describes methods for predicting overall survival in subjects with breast cancer. The application also describes for screening subjects with breast cancer to determine if the breast cancer will be responsive to a breast cancer therapy including gemcitabine. The application further describes methods for treating subjects with breast cancer by screening them for the likelihood of the effectiveness of treating the cancer with a therapy including gemcitabine and administering the therapy in subjects when it is found that gemcitabine is likely to be effective.

The present invention relates to a pharmaceutical cocktail, in particular, effective amounts of gemcitabine, in combination with effective amounts of docetaxel and angiogenesis inhibitor, especially a vascular endothelial growth factor (VEGF) inhibitor, such as bevacizumab for the treatment of cancer, in particular sarcoma, especially soft tissue sarcoma. Pharmaceutical compositions and methods of treating cancer, including sarcoma, especially soft tissue sarcoma (prolonging the patient's life, eliminating the tumor, improving the patient's quality of life, shrinking the tumor, prolonging survival and/or preventing the tumor's metastases) are additional aspects of the present invention.

A dosage regiment for the treatment of a Flaviviridae infection, including a hepatitis C viral infection, that includes administering gemcitabine (or its salt, prodrug or derivative, as described herein) in a dosage range of approximately 50 mg/m<2 >to about 1300 mg/m<2 >per day for between one and seven days (e.g. 1, 2, 3, 4, 5, 6, or 7 days) followed by cessation of therapy. Viral load is optionally monitored over time, and after cessation, viral rebound is monitored. Therapy is not resumed unless a significant viral load is again observed, and then therapy for 1-7 days and more preferred, 1, 2 or 3 days, is repeated. This therapy can be continued indefinitely to monitor and maintain the health of the patient.

Pharmaceutical compositions in the form of ready-to-use preparations of gemcitabine in aqueous solutions in a glass containers having specified dimensional relationships demonstrate long shelf life over a wide range of solution pH values. The ratio of the surface area of the container wetted by the solution to the volume of the solution, expressed in cm² to cm³, is less than 3.4.

The present invention provides methods and compositions for treating cancer by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a nucleoside analog (e.g., gemcitabine) based upon levels of a nucleoside transporter (e.g., hENT1).

Disclosed are a pharmaceutical composition having excellent antitumor activity, and a method for treating a cancer. Specifically, excellent antitumor activity is achieved when 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or an analogous compound thereof, a pharmacologically acceptable salt thereof or a solvate thereof is used in combination with gemcitabine or erlotinib, a pharmacologically acceptable salt thereof or a solvate of any of them.

An objective of the present invention is to provide novel therapeutic agents for cancer, which have an excellent antitumor effect in cancer patients by enhancing their immune function. The present inventors discovered that the administration of at IL-6 inhibitor and/or gemcitabine or a salt thereof to tumor-bearing organisms yields an excellent antitumor T cell response-enhancing effect, and completed the present invention. In addition, the present inventors discovered that the T cell response-enhancing effect produces an excellent antitumor effect.

The present invention provides gemcitabine prodrugs, methods of making gemcitabine prodrugs, pharmaceutical compositions of gemcitabine prodrugs and methods of using gemcitabine prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as cancer or viral infections.

There are provided, inter alia, lipophilic monophosphorylated derivatives of gemcitabine. There are further provided nanoparticles compositions incorporating lipophilic monophosphorylated derivatives of gemcitabine, pharmaceutical compositions thereof, and a method of treating cancer or a viral infection in a subject in need thereof, which method includes administration of a pharmaceutical composition disclosed herein.

A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency. Co-administration of an anti-cancer agent and the interferon alpha conjugate having excellent anti-cancer activity reduces administration dose of anti-cancer agent so as to reduce side effects of anti-cancer agent and increase treatment compliance of patient.

The invention belongs to the field of pharmaceutical chemistry, and relates to a furazan derivative which is prepared by combining a coumarin parent nucleus and an isomer of the coumarin parent nucleus with a furazan oxide through linking of groups with different lengths and structures. It is proved by the experiments that the furazan derivative has excellent effects on inhibiting sensitive human tumour cells and drug-resistant tumor strains, and on inhibiting activity of normal growth of HUVEC for measuring an inhibiting action of neovascularization, and on inhibiting activity of cell proliferation of cis-platinum-resistant A2780 cell strains and gemcitabine-resistant HM231 cell strains. It is shown by an initial pharmacological mechanism that by releasing nitric oxide with the high concentration, the furazan derivative can induce apoptosis of cancer cells, inhibits MEK activity, and obviously inhibits phosphorylation of MEK in an MAPK/ERK channel, thereby generating a significant effect on inhibiting growth of a tumor. According to the composition in the invention, excellent basis for obtaining candidate medicines having inhibition activity of sensitive and drug-resistant tumors and for illustrating the pharmacological action is provided.

The invention discloses a reduced responsive drug-drug conjugate preparation method which is characterized in that the method includes the steps: preparing a camptothecin intermediate (CPT-SS) containing a reduced responsive bond; preparing a reduced responsive drug-drug conjugate (GT-CPT) or (BT-CPT). The reduced responsive drug-drug conjugate has advantages of a small-molecule prodrug and a nano-drug, the uploading capability of the reduced responsive drug-drug conjugate can be effectively improved, the reduced responsive drug-drug conjugate solves the problems of targeting delivery of a current small-molecule prodrug delivery system and controlled release of drug selectivity, and accurate diagnosis and efficient treatment of tumors are facilitated. Gemcitabine (drug) and biotin (target)molecules are introduced, fluorescence of drug molecules can be temporarily shielded, the conjugate is combined with specificities of cancer cells, so that nano-micelles are disassembled and assembled, the fluorescence of the drug molecules can be reduced, and a drug releases drug properties under stimulation response, so that accurate diagnosis and treatment of cancers are combined.

The invention discloses a method for simultaneously detecting multiple anti-tumor drugs in a blood sample. A pretreated sample to be detected is detected by adopting ultra-high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The pretreatment process comprises the following steps: adding serum into a mixed solution of methanol and acetonitrile, oscillating and centrifuging,taking out the centrifuged supernatant, drying, dissolving the dried powder into a methanol aqueous solution, and filtering to obtain a sample to be detected. The method can be used for simultaneously detecting 13 kinds of anti-tumor drugs such as methotrexate, 5-fluorouracil, apatinib, busulfan, carboplatin, cyclophosphamide, docetaxel, gemcitabine, imatinib, illinotecan, lenalidomide, oxaliplatin, paclitaxel and the like in blood.

Drug delivery devices and methods are provided for administering gemcitabine to a patient in need of treatment of bladder cancer by intravesically administering gemcitabine into the bladder of the patient to achieve a sustained concentration of the gemcitabine in urine in the bladder sufficient to produce a therapeutically effective concentration of the gemcitabine in the tissues of the bladder. In embodiments, the local administration into the patient's bladder is at a mean average amount of from 1 mg/day to about 300 mg/day of the gemcitabine (FBE).

The invention discloses a vitamin E succinic acid esterification gemcitabine prodrug which is characterized in that vitamin E succinic acid ester is connected with N4-amino of gemcitabine through an amido bond and the vitamin E succinic acid esterification gemcitabine prodrug has the following formula structure. By means of the vitamin E succinic acid esterification gemcitabine prodrug, the defect that gemcitabine (dFdC) is fast in metabolism is overcome, cycling time of the dFdC is a human body is prolonged, the mode in which the dFdC entering a cell is changed, namely the dFdC no longer enters into the cell relying on a nucleoside transport protein carrier, thus generation of drug resistance is avoided, meanwhile toxic and side effects of the dFdC are reduced furthest, curative effects and bioavailability are improved notably, and the bottleneck that the clinical effect of the dFdC on pancreatic is non-ideal at present is broken.